Cellectar BioSciences Inc. (CLRB)

2.44
0.02 0.81
NASDAQ : Health Technology
Prev Close 2.46
Open 2.44
Day Low/High 2.40 / 2.45
52 Wk Low/High 1.22 / 4.28
Volume 56.43K
Avg Volume 116.30K
Exchange NASDAQ
Shares Outstanding 9.40M
Market Cap 22.64M
EPS -5.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cellectar Announces Oral Presentation At The European Society For Medical Oncology (ESMO) Congress 2019

Cellectar Announces Oral Presentation At The European Society For Medical Oncology (ESMO) Congress 2019

Data from an interim evaluation of CLR 131 in relapsed or refractory DLBCL patients will be presented

Cellectar Appoints Dov Elefant As Chief Financial Officer

Cellectar Appoints Dov Elefant As Chief Financial Officer

Seasoned executive with over two decades of corporate finance and operational leadership experience in the biopharmaceuticals industry to join Cellectar team

CLR 131 Advances To Second Malignant Brain Tumor Cohort Of Ongoing Pediatric Phase 1 Study

CLR 131 Advances To Second Malignant Brain Tumor Cohort Of Ongoing Pediatric Phase 1 Study

Independent Data Monitoring Committee recommends the study continue to higher dose after first dose deemed safe and tolerated

Cellectar Granted Seminal U.S. Patent For Phospholipid-Ether Analogs As Cancer-Targeting Drug Vehicles

Cellectar Granted Seminal U.S. Patent For Phospholipid-Ether Analogs As Cancer-Targeting Drug Vehicles

Covers composition of matter and method of use for proprietary PDCs™ in combination with anti-cancer agents

Cellectar Reports 2017 Financial Results And Provides A Corporate Update

Cellectar Reports 2017 Financial Results And Provides A Corporate Update

Conference call to be held tomorrow at 8:30 a.m. Eastern time

Cellectar Announces Expansion Of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial Of CLR 131

Cellectar Announces Expansion Of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial Of CLR 131

Multiple myeloma cohort exceeded pre-specified criteria for clinically meaningful benefit